Early Treatment of Heart Failure: a Non-interventional Observational Study of Patients With Heart Failure and Initiated on Dapagliflozin in Portugal
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Acronyms EVOLUTION-HF
- Sponsors AstraZeneca
- 19 Jul 2024 Status changed from active, no longer recruiting to completed.
- 26 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 27 Jan 2023 Status changed from not yet recruiting to recruiting.